Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 4/20 | 0.37 |
| ▸ | CASP3 | P42574 | 5/20 | 0.34 |
| ▸ | CASP7 | P55210 | 2/20 | 0.34 |
| ▸ | CASP2 | P42575 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
| ▸ | FER | P16591 | 1/20 | 0.33 |
| ▸ | LTK | P29376 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133934 | 1.00 | GSK3B (0.38) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL9152783 | 1.00 | GSK3B (0.38) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL4206081 | 1.00 | GSK3B (0.38) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL4026807 | 1.00 | GSK3B (0.38) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL8938070 | 1.00 | GSK3B (0.38) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL31036258 | 1.00 | GSK3B (0.38) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL9151570 | 1.00 | GSK3B (0.38) | GSK3BKDM4EALDH1A1GAAHPGD | |
| SCHEMBL1234203 | 0.98 | GSK3B (0.39) | GSK3BKDM4EALDH1A1GAAHPGD | |
| Phthalimide SCHEMBL8559536 | 0.97 | GSK3B (0.44) | GSK3BKDM4EALDH1A1GAAHPGD | |
| Phthalimide SCHEMBL8558696 | 0.96 | GSK3B (0.43) | GSK3BKDM4EALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450348-B2 | Such as 3-[6-(4-Chloro-phenoxy)-hexylamino]-4-(pyridin-4-ylamino)-cyclobut-3-ene-1,2-dione; cancer, tumors; reduced side effects | FORMA TM, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | Valo Health, LLC | 2008-08-21 | — | — | US | disclosed |
| US-7235650-B2 | Derivatized oligonucleotides having improved uptake and other properties | ISIS PHARMACEUTICALS, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7223833-B1 | Peptide nucleic acid conjugates | ISIS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-6919439-B2 | Derivatized oligonucleotides having improved uptake and other properties | ISIS PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030175751-A1 | Derivatized oligonucleotides having improved uptake and other properties | MANOHARAN MUTHIAH (US) | 2003-09-18 | — | — | US | disclosed |
| US-20030064492-A1 | Derivatized oligonucleotides having improved uptake and other properties | ISIS PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| EP-0804456-B1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS INC (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-0804456-A4 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS INC (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5864039-A | THERAPEUTIC TREATMENT OF VARIOUS GASTROINTESTINAL DISEASES, CENTRAL NERVOUS DISORDERS, CARDIOVASCULAR DISORDERS, URINARY DISEASES, UROGENITAL DISORDERS | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-01-26 | — | — | US | disclosed |
| EP-0804456-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0774460-A1 | BENZOIC ACID COMPOUND AND USE THEREOF AS MEDICINE | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996011205-A9 | PEPTIDE NUCLEIC ACID CONJUGATES | — | 1996-05-30 | — | — | WO | disclosed |
| WO-1996011205-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-18 | — | — | WO | disclosed |
| US-5424451-A | Used as cholinesterase activity inhibitors | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1995-06-13 | — | — | US | disclosed |
| US-5302593-A | Aminoalkylcarbamic esters of eseroline suitable for use as chlorinesterase activity inhibitors | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1994-04-12 | — | — | US | disclosed |
| EP-0575954-A1 | Aminoalkylcarbamic esters of eseroline suitable for use as cholinesterase acitivity inhibitors and relative preparation process | MEDIOLANUM FARMACEUTICI S.P.A. (IT) | 1993-12-29 | — | — | EP | disclosed |
| WO-1992014709-A2 | CALCIUM CHANNEL ANTAGONISTS AND METHODOLOGY FOR THEIR IDENTIFICATION | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
| US-4705892-A | Process for preparing alpha,omega-diamino acids | MERCK & CO., INC. (US) | 1987-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200523-A1 | Derivatives of squaric acid with anti-proliferative activity | SQLE, FDFT1, DLD | GSK3B 254/4885KDM4E 2621/4885ALDH1A1 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.